PT - JOURNAL ARTICLE AU - Alexander Y. Trick AU - Fan-En Chen AU - Liben Chen AU - Pei-Wei Lee AU - Alexander C. Hasnain AU - Heba H. Mostafa AU - Karen C. Carroll AU - Tza-Huei Wang TI - Magnetofluidic platform for rapid multiplexed screening of SARS-CoV-2 variants and respiratory pathogens AID - 10.1101/2021.05.10.21256995 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.10.21256995 4099 - http://medrxiv.org/content/early/2021/05/11/2021.05.10.21256995.short 4100 - http://medrxiv.org/content/early/2021/05/11/2021.05.10.21256995.full AB - The rise of highly transmissible SARS-CoV-2 variants brings new challenges and concerns with vaccine efficacy, diagnostic sensitivity, and public health responses in the fight to end the pandemic. Widespread detection of variant strains will be critical to inform policy decisions to mitigate further spread, and post-pandemic multiplexed screening of respiratory viruses will be necessary to properly manage patients presenting with similar respiratory symptoms. In this work, we have developed a portable, magnetofluidic cartridge platform for automated PCR testing in <30 min. Cartridges were designed for multiplexed detection of SARS-CoV-2 with either distinctive variant mutations or with Influenza A and B. The platform demonstrated a limit of detection down to 2 copies/µL SARS-CoV-2 RNA with successful identification of B.1.1.7 and B.1.351 variants. The multiplexed SARS-CoV-2/Flu assay was validated using archived clinical nasopharyngeal swab eluates (n = 116) with an overall sensitivity/specificity of 98.1%/95.2%, 85.7%/100%, 100%/98.2%, respectively, for SARS-CoV-2, Influenza A, and Influenza B. Further testing with saliva (n = 14) demonstrated successful detection of all SARS-CoV-2 positive samples with no false-positives.Competing Interest StatementAYT and T-HW are coinventors on patent PCT/US2019/029937 (A Disposable Reagent Scaffold for Biochemical Process Integration).Funding StatementThis work was supported by funding through the National Institutes of Health (R01AI138978, R01AI137272, R61AI154628).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical swab and saliva specimens were previously collected under Johns Hopkins IRB #00246027.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe main data supporting the results in this study are available within the paper and its supplementary information.